PROTAC Library

Loading...
E3 Ligase
Target
Molecular Weight
to
Your selection
  • Your selection
Structure Catalog Product Name CAS E3 Ligase Target Inquiry
2-Chloro-4-((3S)-8-(4-(4-(2-(6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)-2-oxoethyl)piperazine-1-carbonyl)phenyl)-3-methyl-2,8-diazaspiro[4.5]decan-2-yl)benzonitrile BPL-202553 2-Chloro-4-((3S)-8-(4-(4-(2-(6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)-2-oxoethyl)piperazine-1-carbonyl)phenyl)-3-methyl-2,8-diazaspiro[4.5]decan-2-yl)benzonitrile 2632306-21-7

CRBN

AR

 Inquiry

Molecular Weight: 817.35

Molecular Formula: C44H45ClN8O6

Density: 1.49±0.1 g/cm3

Description: It is a spirocyclic androgen receptor protein degrader used to treat prostate cancer.
2-Chloro-4-((3S)-8-(4-(4-(2-(6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)acetyl)piperazine-1-carbonyl)phenyl)-3-methyl-2,8-diazaspiro[4.5]decan-2-yl)benzonitrile BPL-202554 2-Chloro-4-((3S)-8-(4-(4-(2-(6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)acetyl)piperazine-1-carbonyl)phenyl)-3-methyl-2,8-diazaspiro[4.5]decan-2-yl)benzonitrile 2632306-23-9

CRBN

AR

 Inquiry

Molecular Weight: 817.35

Molecular Formula: C44H45ClN8O6

Density: 1.49±0.1 g/cm3

Description: It is a spirocyclic androgen receptor protein degrader used to treat prostate cancer.
2-Chloro-4-((3S)-8-(4-(4-(2-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)acetyl)piperazine-1-carbonyl)phenyl)-3-methyl-2,8-diazaspiro[4.5]decan-2-yl)benzonitrile BPL-202555 2-Chloro-4-((3S)-8-(4-(4-(2-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)acetyl)piperazine-1-carbonyl)phenyl)-3-methyl-2,8-diazaspiro[4.5]decan-2-yl)benzonitrile 2632306-24-0

CRBN

AR

 Inquiry

Molecular Weight: 803.36

Molecular Formula: C44H47ClN8O5

Density: 1.46±0.1 g/cm3

Description: It is a spirocyclic androgen receptor protein degrader used to treat prostate cancer.
SJ000988497 BPL-202556 SJ000988497 2595365-41-4

CRBN

JAK2

 Inquiry

Molecular Weight: 688.75

Molecular Formula: C36H36N10O5

Density: 1.51±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
SJ000986420 BPL-202557 SJ000986420

CRBN

JAK2

 Inquiry

Molecular Weight: 673.78

Molecular Formula: C37H39N9O4

Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
SJ000988500 BPL-202558 SJ000988500 2595365-45-8

CRBN

JAK2

 Inquiry

Molecular Weight: 716.80

Molecular Formula: C38H40N10O5

Density: 1.46±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
SJ000988498 BPL-202559 SJ000988498 2595365-47-0

CRBN

JAK2

 Inquiry

Molecular Weight: 674.72

Molecular Formula: C35H34N10O5

Density: 1.53±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
SJ000988499 BPL-202560 SJ000988499 2595365-49-2

CRBN

JAK2

 Inquiry

Molecular Weight: 702.78

Molecular Formula: C37H38N10O5

Density: 1.48±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
SJ000986340 BPL-202561 SJ000986340 2595365-51-6

CRBN

JAK2

 Inquiry

Molecular Weight: 704.75

Molecular Formula: C36H36N10O6

Density: 1.52±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
SJ000986050 BPL-202562 SJ000986050 2595365-53-8

CRBN

JAK2

 Inquiry

Molecular Weight: 925.01

Molecular Formula: C46H56N10O11

Density: 1.41±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
SJ000986048 BPL-202563 SJ000986048 2595365-81-2

CRBN

JAK2

 Inquiry

Molecular Weight: 880.96

Molecular Formula: C44H52N10O10

Density: 1.43±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
SJ000986049 BPL-202564 SJ000986049 2595365-55-0

CRBN

JAK2

 Inquiry

Molecular Weight: 836.91

Molecular Formula: C42H48N10O9

Density: 1.44±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
SJ001005328 BPL-202565 SJ001005328 2595365-75-4

CRBN

JAK2

 Inquiry

Molecular Weight: 767.85

Molecular Formula: C41H41N11O5

Density: 1.52±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
(7S)-7-(1-(1-(14-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxatetradecyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide BPL-202566 (7S)-7-(1-(1-(14-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxatetradecyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide 2599844-75-2

CRBN

BTK

 Inquiry

Molecular Weight: 988.07

Molecular Formula: C50H57N11O11

Density: 1.49±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer.
(7S)-7-(1-(1-(17-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide BPL-202567 (7S)-7-(1-(1-(17-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide 2599844-76-3

CRBN

BTK

 Inquiry

Molecular Weight: 1032.12

Molecular Formula: C52H61N11O12

Density: 1.47±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer.
(7S)-7-(1-(1-(17-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide BPL-202568 (7S)-7-(1-(1-(17-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide 2599844-77-4

CRBN

BTK

 Inquiry

Molecular Weight: 1032.12

Molecular Formula: C52H61N11O12

Density: 1.47±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer.
(7S)-7-(1-(1-(20-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18-hexaoxaicosyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide BPL-202569 (7S)-7-(1-(1-(20-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18-hexaoxaicosyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide 2599844-78-5

CRBN

BTK

 Inquiry

Molecular Weight: 1076.18

Molecular Formula: C54H65N11O13

Density: 1.45±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer.
(7S)-7-(1-(1-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-2-oxoethoxy)ethoxy)ethyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide BPL-202570 (7S)-7-(1-(1-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-2-oxoethoxy)ethoxy)ethyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide

CRBN

BTK

 Inquiry

Molecular Weight: 913.95

Molecular Formula: C46H47N11O10

Description: It is a PROTAC that mediates the degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer.
(7S)-7-(1-(3-(4-(4-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)phenyl)propanoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide BPL-202571 (7S)-7-(1-(3-(4-(4-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)phenyl)propanoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide 2599845-02-8

CRBN

BTK

 Inquiry

Molecular Weight: 890.01

Molecular Formula: C50H51N9O7

Density: 1.47±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer.
(7S)-7-(1-(4-(4-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)acetamido)phenyl)butanoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide BPL-202572 (7S)-7-(1-(4-(4-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)acetamido)phenyl)butanoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide 2599845-20-0

CRBN

BTK

 Inquiry

Molecular Weight: 891.99

Molecular Formula: C49H49N9O8

Density: 1.48±0.1 g/cm3

Description: It is a PROTAC that mediates the degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer.

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
  • Email:
Copyright © 2024 BOC Sciences. All Rights Reserved.
Inquiry Basket
Loading ......
Delete selectedGo to checkout